Anti-osteoporosis drugs reduce mortality in cancer patients: A national cohort study of elderly with vertebral fractures.

Autor: Huang CF; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Department of Leisure Services Management, Chaoyang University of Technology, Taichung, Taiwan.; Division of Family Medicine, En Chu Kong Hospital, New Taipei City, Taiwan., Kuo TT; Health Data Analytics and Statistics Center, Office of Data Science, Taipei Medical University, Taipei, Taiwan., Hsu JC; International Ph.D. Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan.; Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan., Kosik RO; Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan., Chan WP; Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.; Department of Radiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Jazyk: angličtina
Zdroj: Annals of the Academy of Medicine, Singapore [Ann Acad Med Singap] 2024 Jan 30; Vol. 53 (1), pp. 6-14. Date of Electronic Publication: 2024 Jan 30.
DOI: 10.47102/annals-acadmedsg.202396
Abstrakt: Introduction: The most prevalent type of fragility fractures is osteoporotic vertebral fractures (OVFs). However, only a few studies have examined the relationship between anti-osteoporosis treatments and malignancy-related mortality following an OVF. The goal of this study is to determine the effect of anti-osteoporosis therapy on mortality in OVF patients with and without cancer.
Method: Data from older people over the age of 65 who were hospitalised for OVFs between 1 January 2003 and 31 December 2018 were analysed retrospectively. A total of 6139 persons getting osteoporosis treatment and 28,950 who did not receive treatment were analysed, together with 2 sets of patients, comprising cancer patients (794) and cancer-free patients (5342), using anti-osteoporosis medication or not, in 1:1 propensity score-matched analyses. The hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.
Results: In all, 35,089 patients with OVFs were included in the population; 29,931 people (85.3%) were women, and the mean (standard deviation) age was 78.13 (9.27) years. Overall survival was considerably higher in those undergoing osteoporosis therapy. This was true both for those without cancer (adjusted HR 0.55; 95% CI 0.51-0.59; P<.0001) as well as those with cancer (adjusted HR 0.72; 95% CI 0.62-0.84; P<.0001). Even among cancer patients, those who received anti-osteoporotic drugs had a lower mortality rate than those who did not.
Conclusion: Our findings suggest that anti-osteoporosis therapy should be initiated regardless of the presence of cancer in the elderly, as it increases survival following OVFs.
Databáze: MEDLINE
Externí odkaz: